Ascletis Completes Enrollment in Phase IIa Study of ASC30
Ascletis Pharma Inc. has recently announced a significant milestone in its clinical research efforts. The company has successfully completed enrollment for its U.S. Phase IIa study of ASC30, a small molecule oral GLP-1 receptor (GLP-1R) agonist aimed at addressing obesity and overweight conditions.
Study Overview and Goals
This Phase IIa trial will span 13 weeks and evaluate the efficacy, safety, and tolerability of two formulations of ASC30, intended for daily oral use. A total of 125 participants, all classified as obese or overweight and burdened with at least one weight-related comorbidity, have been recruited in only slightly over a month.
Rapid Enrollment and Anticipated Outcomes
The swift enrollment of participants highlights the urgent need for innovative treatment options for obesity. Ascletis is eager to gather topline data from this pivotal study, which is projected to be available in the fourth quarter of 2025.
The Unique Formulations of ASC30
In this study, two oral formulations of ASC30 are being evaluated: the first is a standard ASC30 tablet, while the second is a modified version designated ASC30 tablets A1. The primary endpoint for assessing the success of this trial is the mean percentage change in body weight from baseline at the conclusion of Week 13.
Treatment Protocol Details
The study begins with low doses of 1 mg for both formulations, and subsequent doses will be adjusted weekly until reaching the targeted maintenance doses. For formulation 1, the maintenance doses will be 20 mg or 40 mg, while formulation 2 may reach 20 mg, 40 mg, and 60 mg as needed.
Prior Research and Development of ASC30
Prior evaluations of ASC30 were conducted during the Phase Ia single ascending dose study, which showed promising results for both formulations. Notably, formulation 2 exhibited a flatter pharmacokinetic profile compared to formulation 1, suggesting enhanced stability.
Innovative Design of ASC30
ASC30 is touted as the first and only investigational small molecule GLP-1R biased agonist, uniquely designed for daily oral administration and potential monthly subcutaneous injections for patients seeking weight management options.
About ASC30's Unique Properties
ASC30 is characterized by its innovative properties as a GLP-1R biased small molecule agonist. It allows for both oral tablet and subcutaneous injections, providing a versatile treatment approach. This novel chemical entity boasts patent protection extending until 2044 globally, maintaining its market exclusivity for an extended period.
Ascletis Pharma Inc.: Company Profile
As a fully integrated biotechnology firm, Ascletis Pharma Inc. is dedicated to pioneering the development and commercialization of promising therapeutics for metabolic disorders. Utilizing its state-of-the-art Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) platform alongside its Ultra-Long-Acting Platform (ULAP), the company has been able to innovate and advance multiple drug candidates, reinforcing its commitment to transforming treatment landscapes.
Commitment to Obesity Treatment Innovation
With the ongoing development of ASC30, Ascletis exemplifies a commitment to unlocking new possibilities for effective weight management strategies. The inclusion of ASC30 in its portfolio aligns with the company’s vision to address some of the most challenging metabolic health issues faced globally.
Frequently Asked Questions
What is the ASC30 study about?
The ASC30 study is a Phase IIa trial assessing the safety and efficacy of a new oral GLP-1 receptor agonist for treating obesity and overweight conditions.
How many participants are involved in the study?
The study has enrolled a total of 125 participants, all of whom are considered obese or overweight.
What are the expected outcomes of this study?
The primary endpoint is to measure the mean percentage change in body weight from the baseline after 13 weeks.
What unique characteristics does ASC30 have?
ASC30 has been designed to offer both oral and subcutaneous dosage forms, making it versatile for treatment.
When can we expect topline data from the study?
Topline data from the study is anticipated to be released in the fourth quarter of 2025.
